Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells

Oncotarget. 2017 Jun 20;8(25):41091-41101. doi: 10.18632/oncotarget.17056.

Abstract

Multiple myeloma is a fetal form of plasma cell malignancy characterized by abnormal clonal proliferation of plasma cells. Especially, the canonical Wnt signaling pathway mediated by β-catenin is activated in multiple myeloma cells, stimulating their proliferation. Here, we investigated the relationship between interleukin-6-induced proliferation of multiple myeloma cells and Traf2- and Nck-interacting kinase (TNIK) expression in Wnt signaling. Interleukin-6 increased the proliferation of multiple myeloma cells and TNIK mRNA and protein expression. In addition, we examined the effect on TNIK of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib and whether inhibition of TNIK suppresses the interleukin-6-induced proliferation of multiple myeloma cells. KY-05009 and dovitinib synergistically inhibited interleukin-6-stimulated proliferation and induced apoptosis through the inhibition of Wnt signaling in MM cells. Our results provide crucial information that TNIK is involved in the interleukin-6-dependent proliferation of multiple myeloma cells and inhibition of Wnt signaling involving TNIK could be a therapeutic strategy for the treatment of interleukin-6-dependent multiple myeloma.

Keywords: IL-6; KY-05009; TNIK; Wnt signaling; multiple myeloma.

MeSH terms

  • Aniline Compounds / pharmacology*
  • Apoptosis / drug effects
  • Apoptosis / genetics
  • Benzimidazoles / pharmacology*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects*
  • Cell Proliferation / genetics
  • Cell Survival / drug effects
  • Cell Survival / genetics
  • Drug Synergism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Germinal Center Kinases
  • Humans
  • Interleukin-6 / pharmacology*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / metabolism
  • Multiple Myeloma / pathology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Serine-Threonine Kinases / antagonists & inhibitors*
  • Protein Serine-Threonine Kinases / genetics
  • Protein Serine-Threonine Kinases / metabolism
  • Quinolones / pharmacology*
  • Thiazoles / pharmacology*
  • Wnt Signaling Pathway / drug effects*
  • Wnt Signaling Pathway / genetics
  • beta Catenin / genetics
  • beta Catenin / metabolism

Substances

  • 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
  • 5-(4-methylbenzamido)-2-(phenylamino)thiazole-4-carboxamide
  • Aniline Compounds
  • Benzimidazoles
  • Germinal Center Kinases
  • Interleukin-6
  • Protein Kinase Inhibitors
  • Quinolones
  • Thiazoles
  • beta Catenin
  • Protein Serine-Threonine Kinases
  • TNIK protein, human